Ligand Pharmaceuticals LGND Elutia (CorMatrix) — Financial Royalty Assets, Allowance

Other product segments

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

NOVRoyalty — Contract With Customer Receivable After Allowance For Credit Loss

$43M+231%

WECCorporate and Other — Allowance for credit losses

$0—

KREFAllowance for credit losses

$258.68M+81.7%

WALCorporate & Other — Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest

$0—

AESOther Entity — Financing Receivable, Allowance for Credit Loss

$0—

Questions, answered.

What is Ligand Pharmaceuticals's elutia (cormatrix) — financial royalty assets, allowance?

Ligand Pharmaceuticals (LGND) reported elutia (cormatrix) — financial royalty assets, allowance of $1.13M in Q1 2026.

What does elutia (cormatrix) — financial royalty assets, allowance mean?

This reflects the contra-asset account established to account for potential uncollectibility or expected credit losses related to royalty assets from the Elutia and CorMatrix segments. It represents management's estimate of the portion of royalty receivables that may not be realized. A significant increase in this allowance may indicate deteriorating credit quality or collection risks associated with the underlying licensees.